RT Journal Article
SR Electronic
T1 Rapid vigilance and episodic memory decrements in COVID-19 survivors
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.06.21260040
DO 10.1101/2021.07.06.21260040
A1 Zhao, Sijia
A1 Shibata, Kengo
A1 Hellyer, Peter J.
A1 Trender, William
A1 Manohar, Sanjay
A1 Hampshire, Adam
A1 Husain, Masud
YR 2021
UL http://medrxiv.org/content/early/2021/07/08/2021.07.06.21260040.abstract
AB Recent studies indicate that COVID-19 infection can lead to serious neurological consequences in a small percentage of individuals. However, in the months following acute illness, many more suffer from fatigue, low motivation, disturbed mood, poor sleep and cognitive symptoms, colloquially referred to as ‘brain fog’. But what about individuals who do not report any ongoing symptoms after recovering from COVID-19? Here we examined a wide range of cognitive functions critical for daily life (including sustained attention, memory, motor control, planning, semantic reasoning, mental rotation and spatial-visual attention) in people who had previously suffered from COVID-19 but were not significantly different from a control group on self-reported fatigue, forgetfulness, sleep abnormality, motivation, depression, anxiety and personality profile. COVID-19 survivors displayed significantly worse episodic memory (up to 6 months post infection) and greater decline in vigilance and motivation with time on task (for up to 9 months). Overall, the results show that chronic cognitive impairments following COVID-19 are evident on objective testing even amongst those who do not report a greater symptom burden. Importantly, in the sample tested here, these were not significantly different from normal after six-nine months, demonstrating evidence of recovery over time.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Wellcome Trust and NIHR Oxford Biomedical Research Centre. S.Z. and M.H. were funded by the Wellcome Trust (206330/Z/17/Z). S.G.M. was funded by an MRC Clinician Scientist Fellowship (MR/P00878/X). K.S. was funded by the Berrow Foundation. A.H. was supported by the UK Dementia Research Institute Care Research, the National Institute for Health Research (NIHR) Technology Centre and Imperial Biomedical Research Centre. P.J.H. was supported by the NIHR Biomedical Research Centre, South London and Maudsley NHS Foundation Trust and King's College London. W.T was funded by the Engineering and Physical Sciences Research Council (EPSRC) through the Imperial College CDT for Neurotechnology. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics were approved through South Central Oxford A Research Ethics Committee. (Ethics Approval Reference: 18/SC/0448)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data supporting the findings of this study are available from the corresponding author, upon reasonable request. A demo of the vigilance task is available at https://run.pavlovia.org/sijiazhao/vigilance_english_demo (please use the Chrome internet browser on a desktop computer). The experimental code is available at https://gitlab.pavlovia.org/sijiazhao/vigilance_english_demo.COVID-19Coronavirus disease 2019 caused by the Coronavirus SARS-CoV-2